- Home
- OCFC vs ANAB Comparison
OCFC vs ANAB Comparison
Compare OCFC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- ANAB
- Stock Information
- Founded
- OCFC 1902
- ANAB 2005
- Country
- OCFC United States
- ANAB United States
- Employees
- OCFC N/A
- ANAB N/A
- Industry
- OCFC Major Banks
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- ANAB Health Care
- Exchange
- OCFC Nasdaq
- ANAB Nasdaq
- Market Cap
- OCFC 861.7M
- ANAB 759.5M
- IPO Year
- OCFC 1996
- ANAB 2017
- Fundamental
- Price
- OCFC $16.50
- ANAB $20.61
- Analyst Decision
- OCFC Buy
- ANAB Buy
- Analyst Count
- OCFC 4
- ANAB 9
- Target Price
- OCFC $21.75
- ANAB $34.86
- AVG Volume (30 Days)
- OCFC 331.8K
- ANAB 828.5K
- Earning Date
- OCFC 04-24-2025
- ANAB 05-08-2025
- Dividend Yield
- OCFC 4.84%
- ANAB N/A
- EPS Growth
- OCFC N/A
- ANAB N/A
- EPS
- OCFC 1.65
- ANAB N/A
- Revenue
- OCFC $375,233,000.00
- ANAB $91,280,000.00
- Revenue This Year
- OCFC N/A
- ANAB N/A
- Revenue Next Year
- OCFC $12.62
- ANAB $37.76
- P/E Ratio
- OCFC $10.01
- ANAB N/A
- Revenue Growth
- OCFC N/A
- ANAB 432.03
- 52 Week Low
- OCFC $14.03
- ANAB $12.21
- 52 Week High
- OCFC $21.87
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- OCFC 54.23
- ANAB 61.53
- Support Level
- OCFC $15.59
- ANAB $15.40
- Resistance Level
- OCFC $16.93
- ANAB $22.29
- Average True Range (ATR)
- OCFC 0.78
- ANAB 1.49
- MACD
- OCFC 0.18
- ANAB 0.30
- Stochastic Oscillator
- OCFC 83.71
- ANAB 75.62
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).